Moderna Stock Faces Crucial Test as ESMO Data Looms
Moderna's stock has been on a wild ride over the past year, surging by 503% after announcing its mRNA cancer vaccine breakthrough with Merck. However, since reaching its 52-week high of $176.66, the stock has pulled back by 18%, currently trading at $144.83 as of September 3.
Two key factors have contributed to this decline: concern over dilution following a $2 billion convertible senior notes offering due in 2032, and a setback for rival BioNTech's Phase 2 colorectal cancer mRNA trial.
From a technical standpoint, the stock has a strong buy signal with its daily RSI at 63.1, MACD indicating a buy, and ADX showing a developing trend. However, the weekly RSI is in overbought territory at ~79, which could indicate near-term exhaustion.
The next critical catalyst for Moderna's stock will be the presentation of full Phase 3 intismeran data at the ESMO 2026 Congress on October 26-27. A disappointing outcome from this event could trigger a sharp reversal in the stock price.